Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
1 competitor in Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
View Full LandscapeTarget Indication
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Clinical Trial
NCT04136171Last updated: 12/4/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Wainzua
Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
View on EMA